The shot handles how much. Nothing is handling what.

The first few weeks are genuinely startling. The constant negotiation with food, the thing people have started calling food noise, just stops. You forget lunch. You leave half the plate. The scale moves in a way it has never moved before, and for a while that is the whole story.

Then somewhere around month three a different question shows up, usually quietly, usually at the end of a day when you realise you have eaten a yogurt and most of a bagel.

You are eating a fraction of what you used to. Is any of it the right thing?

Nobody handed you an answer with the pen. The medication regulates appetite. It has no opinion about protein, or iron, or whether the small amount you are managing to eat covers what your body still needs to run on.

The number that reframes the whole thing

A study of 387 adults taking GLP-1 or dual GIP/GLP-1 medications measured what people were actually eating. The averages were lower than most people expect.

Dietary intake patterns and nutritional adequacy among adults treated with GLP-1 or dual GIP/GLP-1 receptor agonists, preliminary study, 2025.

Read that as arithmetic rather than as a warning. At 2,000 calories a day you can eat carelessly and still stumble into most of what you need, because volume covers for you. At 753, volume is not covering for anything. Every bite has to carry more than it used to, and almost nobody is given a plan for that.

The plateau nobody warns you about

The other thing that shows up around month six is that the scale stops.

When GenoPalate surveyed 100 people interested in its GLP-1 program, weight plateau was the single most-cited challenge. The write-in answers were more specific than the checkbox:

Another put it in five words: “I would like to know why my body is stalled out at a 30 bmi.”

A plateau is the moment the medication stops being the whole answer. Appetite suppression got you to a new set point, and now the variables that decide what happens next are the ones nobody has measured yet: what you are actually eating, what you are absorbing, how much lean mass you kept, and what your own biology does with all of it.

Not all weight is the same weight

This is the part that turns a nutrition question into a longer one.

When you lose weight quickly, some of what leaves is fat and some of it is lean mass, which mostly means muscle. A 2024 systematic review and network meta-analysis put lean mass at roughly 25% of total weight lost on these medications. The STEP 1 trial reported a higher figure still, with lean mass accounting for 45.5% of the weight lost. Researchers at the University of Alberta have described muscle accounting for as much as 39% over a 36 to 72 week window.

Figures vary widely by study, population and how body composition was measured. Some loss of lean mass is expected and normal with any significant weight loss, including diet-only weight loss. The debate in the literature is about the size of it and what it means over time, not whether it happens.

Muscle is not a cosmetic asset. It is where most of your glucose gets used, it is a large share of your resting metabolic rate, and it is the single best predictor of whether you can carry your own shopping at 75. Losing weight is the goal. Losing muscle is a cost, and it is a cost that gets charged later.

What reduces that cost is not a secret and it is not a supplement: resistance training and adequate protein. Which brings the problem back around, because 33.4 grams of protein a day is not adequate protein for anybody.

And then there is the part after

Most people do not stay on these medications forever. Cost, side effects, supply and insurance all intervene, and one industry analysis cited by GenoPalate puts early discontinuation at over half of users.

The STEP 1 trial extension followed people after they stopped semaglutide. Within a year of withdrawal, participants had regained roughly two thirds of the weight they had lost. Average loss went from 17.3% at week 68 to a net 5.6% at week 120.

Here is why that matters more than it first appears. If a meaningful share of what you lost on the way down was muscle, and what you regain on the way back up is mostly fat, you can arrive back at your starting weight with a worse body composition than you began with.

Same number on the scale. Less muscle underneath it. That is the outcome worth spending real effort to avoid, and the effort has to happen while you are still on the medication, not after.

Why this is the one case where personalization stops being optional

When you have 2,000 calories to work with, a generic recommendation is fine. There is enough room in the day to be approximately right and still cover your needs.

When you have 750, being approximately right is not good enough, and a general-purpose multivitamin is a guess at which gaps are yours. The fewer calories you have to spend, the more it matters that you spend them on the right things.

GenoPalate reads more than 650,000 genetic variants from a saliva sample in a CLIA-certified, CAP-accredited US lab, and scores over 300 whole foods against what it finds. For someone eating normally that is useful. For someone eating a third of what they used to, it is the difference between a small amount of food that covers you and a small amount of food that does not.

What this is not, said plainly

• It is not medical advice and it is not a treatment. GenoPalate does not prescribe, adjust or replace anything. Your prescriber runs your medication. Talk to them before you change how you eat, particularly if you are managing a health condition.
• It will not stop muscle loss on its own. Nothing you read is a substitute for resistance training and eating enough protein. A report tells you where your gaps are. It does not lift anything for you.
• It is not a diagnosis. It will not tell you that you have a deficiency or a disease. That is what bloodwork and your doctor are for, and the GLP-1 program includes biomarker testing precisely because genetics alone does not answer that question.
• The research is young. These medications are new enough that the long-term body composition literature is still being written, and the studies quoted here disagree with each other on magnitude. We have linked the numbers rather than rounding them into a slogan.

The program built for this specific problem

GenoPalate runs a wellness program designed around GLP-1 users rather than adapted for them. It pairs the DNA nutrition report with blood biomarker testing, so you are working from what your genetics suggest and what your bloodwork actually shows, plus biweekly 1-on-1 sessions with a registered dietitian who works on protein, movement and side effect management.

In GenoPalate's own member survey, 94% rated their coach extremely or very effective at explaining their personalized recommendations, and 92% left a session confident about reaching their goals.

Questions people ask

The window is while you are still on it

The medication bought you something genuinely valuable: a period where eating less is not a fight. That window is the easiest time you will ever have to fix what you eat, and it is also the only time the fix compounds, because whatever you build now is what is standing there when the prescription ends.

The shot already decided how much. What goes in is still yours to decide.

Sources: dietary intake and nutritional adequacy in adults on GLP-1 or dual GIP/GLP-1 agonists (2025, n=387); micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy, narrative review, Clinical Obesity; effect of GLP-1 receptor agonists and co-agonists on body composition, systematic review and network meta-analysis (2024); Wilding et al., weight regain and cardiometabolic effects after withdrawal of semaglutide, the STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022); University of Alberta commentary on muscle loss with obesity medications.